499 / 1816
Study
name
Study design
Main patient inclusion criteria
Aimed
number of
patients
Recruit-
ment
LORIS
(UK)
Randomizes between
active surveillance versus
surgery
± RT
± Tamoxifen
Yearly mammography
Female, > 46 years; screen detected or incidental
microcalcification (unilateral or bilateral);
Nonhigh-grade DCIS confirmed by local
pathologist on either small volume core biopsy
or VACB
932
Since June
2014
LORD
(EORTC)
Randomizes between
active surveillance versus
surgery
± RT
± Tamoxifen
Yearly mammography
Woman of age ≥45 years, Calcifications only
lesions, detected by population-based or
opportunistic screening mammography;
Representative vacuum-assisted core biopsy
with pure low-grade DCIS
1240
Since
December
2015
CALGB
40903
Neoadjuvant treatment
with letrozol for 6 month
with MRT controls at 3 and
6 month
Resection in case of
progression
DCIS without invasive cancer or with
microinvasion on diagnostic core biopsy;
Estrogen and/or progesterone receptor positive;
postmenopausal patient
115
Since
February
2012
Ongoing Trials for ductal carcinoma in situ